Wed, Jul 23, 2014, 12:38 AM EDT - U.S. Markets open in 8 hrs 52 mins

Recent

% | $
Click the to save as a favorite.

ONYX Pharmaceuticals, Inc. Message Board

  • johnpapas893 johnpapas893 Oct 5, 2012 2:22 PM Flag

    Goldman Sachs raises PT to 98.00

    Goldman Sachs Sets Onyx Pharmaceuticals Price Target at $98.00 (ONXX)

    October 5th, 2012 - 0 comments - Filed Under - by Trevor Kearing

    Investment analysts at Goldman Sachs raised their target price on shares of Onyx Pharmaceuticals (NASDAQ: ONXX) from $88.00 to $98.00 in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock.

    The analysts wrote, “We are highly encouraged by the results of our survey and are raising our above-consensus Kyprolis estimates, which drive our non-GAAP EPS estimates higher. Our survey points to high awareness of the drug (40% of US physicians have already prescribed), prescribing in academic and private practice settings, usage of the drug in the US across all lines of therapy (surprisingly including some first-line), the majority of dosing at labeled dose, no significant reimbursement issues and nothing new on the safety front.”

    Onyx Pharmaceuticals traded up 4.03% on Friday, hitting $89.33. Onyx Pharmaceuticals has a 1-year low of $30.53 and a 1-year high of $87.47. The company has a market cap of $5.815 billion and a price-to-earnings ratio of 318.04.

    Onyx Pharmaceuticals last released its earnings data on Wednesday, August 1st. The company reported ($0.68) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.69) by $0.01. Onyx Pharmaceuticals’s revenue was up 7.0% compared to the same quarter last year. On average, analysts predict that Onyx Pharmaceuticals will post $-3.26 earnings per share for the current fiscal year.

    ONXX has been the subject of a number of other recent research reports. Analysts at Bank of America reiterated a “buy” rating on shares of Onyx Pharmaceuticals in a research note to investors on Monday. They now have a $89.00 price target on the stock. Separately, analysts at Brean Murray initiated coverage on shares of Onyx Pharmaceuticals in a research note to investors on Thursday, September 27th. They set a “buy” rating and a $98.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Onyx Pharmaceuticals in a research note to investors on Wednesday, September 19th.

    Sentiment: Strong Buy

 
ONXX
124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.